HomeCompareLVTX vs CL

LVTX vs CL: Dividend Comparison 2026

LVTX yields 114.94% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVTX wins by $7.01M in total portfolio value
10 years
LVTX
LVTX
● Live price
114.94%
Share price
$1.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.05M
Annual income
$2,599,161.52
Full LVTX calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — LVTX vs CL

📍 LVTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVTXCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVTX + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVTX pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVTX
Annual income on $10K today (after 15% tax)
$9,770.11/yr
After 10yr DRIP, annual income (after tax)
$2,209,287.29/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, LVTX beats the other by $2,204,653.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVTX + CL for your $10,000?

LVTX: 50%CL: 50%
100% CL50/50100% LVTX
Portfolio after 10yr
$3.54M
Annual income
$1,302,306.61/yr
Blended yield
36.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

LVTX
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$3.75
+115.5% upside vs current
Range: $1.50 — $6.00
Altman Z
-4.7
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVTX buys
0
CL buys
0
No recent congressional trades found for LVTX or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVTXCL
Forward yield114.94%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$7.05M$41.0K
Annual income after 10y$2,599,161.52$5,451.69
Total dividends collected$6.38M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$3.75$92.45

Year-by-year: LVTX vs CL ($10,000, DRIP)

YearLVTX PortfolioLVTX Income/yrCL PortfolioCL Income/yrGap
1← crossover$22,194$11,494.25$11,014$313.84+$11.2KLVTX
2$47,590$23,841.72$12,200$415.44+$35.4KLVTX
3$98,699$47,777.67$13,607$553.09+$85.1KLVTX
4$198,214$92,606.18$15,301$741.41+$182.9KLVTX
5$385,900$173,811.71$17,374$1,002.00+$368.5KLVTX
6$729,168$316,254.64$19,958$1,367.44+$709.2KLVTX
7$1,338,687$558,477.43$23,243$1,887.87+$1.32MLVTX
8$2,390,633$958,237.97$27,512$2,642.43+$2.36MLVTX
9$4,157,254$1,599,276.16$33,197$3,759.22+$4.12MLVTX
10$7,047,423$2,599,161.52$40,973$5,451.69+$7.01MLVTX

LVTX vs CL: Complete Analysis 2026

LVTXStock

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Full LVTX Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this LVTX vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVTX vs SCHDLVTX vs JEPILVTX vs OLVTX vs KOLVTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.